The U.S. Food and Drug Administration is approving more novel pharmaceutical drugs based on single clinical trials and with less public disclosure about those trials than was the norm just a few years ago, a pair of recent studies from Oregon State University found.
In a new perspective piece published in the Feb. 5 issue of Science, pharmacologist Namandje Bumpus, Ph.D. — who recently became the first African American woman to head a Johns Hopkins University School of Medicine department, and is the only African American woman leading a pharmacology department in the country — outlines the molecular origins for differences in how well certain drugs work among distinct populations. She also lays out a four-part plan to improve the equity of drug development.
Michael Gusmano, a Rutgers bioethicist and health policy expert, is available to discuss the pledge by drug manufacturers to uphold ethical standards and scientific principles in the global quest for a COVID-19 vaccine. “The safety pledge indicates the pharmaceutical industry…
For patients who receive a heart transplant in the near future, the old adage, “Good things come in small packages,” may become words to live by. In a recent study, researchers at Johns Hopkins Medicine and the National Cancer Institute (NCI) demonstrated in mice that they can easily deliver a promising anti-rejection drug directly to the area surrounding a grafted heart by packaging it within a tiny three-dimensional, protein gel cocoon known as a hydrogel. Best of all, the researchers say that the release of the drug is spread out over time, making it highly regulatable and eliminating the need for daily medication to keep rejection in check.
Recently, several physicians hosted a press conference in which one physician claimed that the combination of hydroxychloroquine, the antibiotic azithromycin and the mineral zinc could cure COVID-19. The video footage of that press conference went viral on social media, and soon many social media platforms removed the videos for providing inaccurate, non-scientifically backed claims. But questions from the public may still remain.
In a pilot study of people living with HIV or high levels of cholesterol, Johns Hopkins Medicine researchers found that a six-week course of a cholesterol-lowering medication improved the function of the coronary arteries that provide oxygen to the heart.
During the COVID-19 pandemic, Johns Hopkins Medicine Media Relations is focused on disseminating current, accurate and useful information to the public via the media. As part of that effort, we are distributing our “COVID-19 Tip Sheet: Story Ideas from Johns Hopkins” every Tuesday throughout the duration of the outbreak.